Connect your AI

Tango Therapeutics TNGX Earnings yield

Earnings yield at other companies

Bristol-Myers SquibbBMY

5.9%+1.6pp

AmgenAMGN

4.1%+0.6pp

Gilead SciencesGILD

5.3%+1.1pp

ExelixisEXEL

7.4%+1.1pp

Cogent Biosciences, Inc.COGT

-5.7%-2.6pp

CG OncologyCGON

-3.3%-1.0pp

Other financials

Income statement

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

Market cap$4.55B+1,915%

Enterprise value$4.43B+2,204%

P/S79.9×+74.4×

Profitability

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

net income/market cap=-3.6%

Based on trailing twelve months.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Tango Therapeutics's earnings yield?: Tango Therapeutics (TNGX) reported earnings yield of -3.6% in Q1 2026.
How has Tango Therapeutics's earnings yield changed year-over-year?: Tango Therapeutics's earnings yield increased by 96.0% year-over-year, from -89.3% to -3.6%.
What is the long-term trend for Tango Therapeutics's earnings yield?: Over 5 years (2020 to 2025), Tango Therapeutics's earnings yield has grown at a 14.5% compound annual growth rate (CAGR), from -4.3% to -8.5%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.